Taking into consideration new treatment strategies that have become available during the past decade, including targeted therapy and immunotherapy, survival of stage IV melanoma patients has improved, with over 70% survival rates at one year with BRAF plus MEK inhibitor treatment or with PD-1 blockade, but long follow-up is needed to determine more accurate conclusions [21]. The gene discussed is BRAF; the disease is melanoma.